HVTN 111

A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants,

Enrollment Opened

Objectives

-To evaluate safety and tolerability of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

-To evaluate  immune responses of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

Trial design

Multicenter, randomized, controlled, double-blind trial conducted in six sites in Southern African countries.

Funder/Sponsor

NIH/DAIDS HVTN

 

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya RT @MedicoPressTZ: 10 Years Of Consistency, Uniqueness and Great Scientific Output 📍Dar-es-Salaam, MUHAS, Upanga Campus Brace for a major…
8hreplyretweetfavorite
NIMRMbeya RT @TBtrials_StAnd: Many congratulations to Dr. Mtafya! It was great having you and some of the @NIMRMbeya team members in St Andrews for a…
NIMRMbeya 🎉 Congratulations to our very own Dr. @BarikiMtafya4 👏👏 and much appreciation to Dr.@SabiitiwWilber for your guidan… https://t.co/dAyzf9vxmG
NIMRMbeya 📢 new paper alert Results from @PanACEA_II showing that MBLA is better than MGIT TTD at predicting relapse in #TB p… https://t.co/e9KQFDEEJU
NIMRMbeya RT @ifakarahealth: JOBS: Ifakara @ifakarahealth and the @SwissTPH invite applications from Tanzanians to fill 2 fully-funded three-year doc…
© 2017 NIMR - Mbeya Medical Research Center